Second-Generation (Atypical) Antipsychotics

Second-generation, or atypical, antipsychotics are the newer drug class introduced from the reintroduction of clozapine onward. They were defined pharmacologically by combining dopamine D2 antagonism with relatively strong serotonin 5-HT2A antagonism, an approach associated with fewer extrapyramidal motor effects but, for many agents, a greater liability for metabolic adverse effects.

Definition

Second-generation (atypical) antipsychotics are antipsychotic agents characterised pharmacologically by combined dopamine D2 and serotonin 5-HT2A antagonism (or, for some, D2 partial agonism), associated with a lower rate of extrapyramidal effects than the typical agents.

Scope

This topic covers what distinguishes the atypical antipsychotics: their mixed serotonin-dopamine receptor profile, the rationale for the 'atypical' label, the prototype role of clozapine, and the shift in side-effect burden from motor toward metabolic effects. It is a reference description and does not provide dosing or prescribing advice.

Core questions

• What pharmacological feature distinguishes atypical from typical antipsychotics?
• Why is clozapine considered the prototype of the class?
• How does the side-effect burden shift from motor to metabolic effects?
• Do atypicals offer a consistent efficacy advantage over typical agents?

Key concepts

• Combined D2 and 5-HT2A antagonism
• Clozapine as prototype
• Lower extrapyramidal liability
• Metabolic side-effect burden
• D2 partial agonism (e.g., aripiprazole-type agents)

Key theories

Serotonin-dopamine ratio definition of atypicality

Meltzer and colleagues proposed that drugs with a high ratio of serotonin 5-HT2 to dopamine D2 receptor affinity form the 'atypical' subclass, offering a pharmacological criterion for the otherwise clinical distinction.

Mechanisms

Atypical antipsychotics retain dopamine D2 antagonism but add substantial serotonin 5-HT2A antagonism, and some act as D2 partial agonists rather than full antagonists. Meltzer's analysis framed a high serotonin-to-dopamine affinity ratio as the defining feature of the subclass. This mixed profile is associated with a lower propensity to cause extrapyramidal effects at therapeutic doses, but several agents carry strong histaminergic and metabolic actions that shift the principal adverse-effect burden toward weight gain and metabolic disturbance.

Clinical relevance

Atypical antipsychotics are widely used for psychotic and some mood disorders and are valued for their reduced motor side-effect liability, though their metabolic effects are an important counterweight. Clozapine occupies a distinct place as the agent with evidence in treatment-resistant illness. This entry describes the subclass at a conceptual level and is not a guide to prescribing or to individual treatment decisions.

Evidence & guidelines

Pragmatic trials such as CATIE and large meta-analyses show that, with the notable exception of clozapine, atypical agents do not uniformly outperform typical drugs on efficacy and that their advantage lies mainly in a different side-effect profile. Reviews of physical-health risk highlight the metabolic burden associated with several agents, a recurrent theme in current guidelines.

History

Clozapine, withdrawn after reports of agranulocytosis and later reintroduced under monitoring, demonstrated that an antipsychotic could be effective with little extrapyramidal liability, prompting the search for similarly 'atypical' agents. Meltzer's serotonin-dopamine framework gave the emerging class a pharmacological rationale, and a wave of second-generation drugs followed through the 1990s and 2000s, later tempered by recognition of their metabolic effects.

Debates

Do atypical antipsychotics justify their status as a distinct, superior class?

Large trials and meta-analyses indicate that the second-generation drugs are heterogeneous and that, apart from clozapine, their efficacy advantage over typical agents is small, leading some authors to question the clinical usefulness of the atypical category.

Key figures

• Herbert Meltzer
• Jeffrey Lieberman
• Stefan Leucht
• Christoph Correll

Seminal works

• meltzer-1989
• lieberman-2005
• leucht-2009

Frequently asked questions

What makes an antipsychotic 'atypical'?

Atypical agents combine dopamine D2 antagonism with relatively strong serotonin 5-HT2A antagonism (and in some cases D2 partial agonism); pharmacologically this is often summarised as a high serotonin-to-dopamine affinity ratio, associated with fewer motor side effects.

Why is clozapine treated as special among atypical antipsychotics?

Clozapine was the agent that showed antipsychotic efficacy with very low extrapyramidal liability and has evidence in treatment-resistant illness, but it requires monitoring because of the risk of agranulocytosis.